Literature DB >> 27662010

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Andrew S Artz1, Brent Logan2,3, Xiaochun Zhu2, Gorgun Akpek4, Rodrigo Martino Bufarull5, Vikas Gupta6, Hillard M Lazarus7, Mark Litzow8, Alison Loren9, Navneet S Majhail10, Richard T Maziarz11, Philip McCarthy12, Uday Popat13, Wael Saber2, Stephen Spellman14, Olle Ringden15,16, Amittha Wickrema17, Marcelo C Pasquini2, Kenneth R Cooke.   

Abstract

We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and ferritin prior to allogeneic hematopoietic cell transplantation. The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoing unrelated donor transplant reported to the Center for International Blood and Marrow Transplant Research. C-reactive protein and ferritin were centrally quantified by ELISA from cryopreserved plasma whereas each center provided pre-transplant albumin. In multivariate analysis, transplant-related mortality was associated with the pre-specified thresholds of C-reactive protein more than 10 mg/L (P=0.008) and albumin less than 3.5 g/dL (P=0.01) but not ferritin more than 2500 ng/mL. Only low albumin independently influenced overall mortality. Optimal thresholds affecting transplant-related mortality were defined as: C-reactive protein more than 3.67 mg/L, log(ferritin), and albumin less than 3.4 g/dL. A 3-level biomarker risk group based on these values separated risks of transplant-related mortality: low risk (reference), intermediate (HR=1.66, P=0.015), and high risk (HR=2.7, P<0.001). One-year survival was 74%, 67% and 56% for low-, intermediate- and high-risk groups. Routinely available pre-transplant biomarkers independently risk-stratify for transplant-related mortality and survival. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27662010      PMCID: PMC5394859          DOI: 10.3324/haematol.2016.145847

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Rainer F Storb; Brenda M Sandmaier; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Smita Bhatia; Fabiana Ostronoff; H Joachim Deeg; Karen L Syrjala; Elihu Estey; David G Maloney; Frederick R Appelbaum; Paul J Martin; Barry E Storer
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release.

Authors:  A M Konijn; C Hershko
Journal:  Br J Haematol       Date:  1977-09       Impact factor: 6.998

4.  Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons.

Authors:  David B Reuben; Anna I Cheh; Tamara B Harris; Luigi Ferrucci; John W Rowe; Russell P Tracy; Teresa E Seeman
Journal:  J Am Geriatr Soc       Date:  2002-04       Impact factor: 5.562

5.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Authors:  Jennifer E Vaughn; Barry E Storer; Philippe Armand; Roberto Raimondi; Christopher Gibson; Alessandro Rambaldi; Fabio Ciceri; Rosi Oneto; Benedetto Bruno; Paul J Martin; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

6.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.

Authors:  Raymond Wong; Sergio A Giralt; Thomas Martin; Daniel R Couriel; Athanasios Anagnostopoulos; Chitra Hosing; Borje S Andersson; Pedro Cano; Munir Shahjahan; Cindy Ippoliti; Elihu H Estey; John McMannis; James L Gajewski; Richard E Champlin; Marcos de Lima
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

7.  Serum albumin level and physical disability as predictors of mortality in older persons.

Authors:  M C Corti; J M Guralnik; M E Salive; J D Sorkin
Journal:  JAMA       Date:  1994-10-05       Impact factor: 56.272

8.  Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation.

Authors:  Simone Cunha Maradei; Angelo Maiolino; Alexandre Mello de Azevedo; Marta Colares; Luis Fernando Bouzas; Marcio Nucci
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

9.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

10.  Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.

Authors:  Michael A Pulsipher; Kenneth M Boucher; Donna Wall; Haydar Frangoul; Michel Duval; Rakesh K Goyal; Peter J Shaw; Ann E Haight; Michael Grimley; Stephan A Grupp; Morris Kletzel; Richard Kadota
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

View more
  16 in total

1.  Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.

Authors:  Anthony D Sung; Shekeab Jauhari; Sharareh Siamakpour-Reihani; Arati V Rao; Janet Staats; Cliburn Chan; Everett Meyer; Vijayakrishna K Gadi; Andrew B Nixon; Jing Lyu; Jichun Xie; Lauren Bohannon; Zhiguo Li; Christopher S Hourigan; Laura W Dillon; Hong Yuen Wong; Rebecca Shelby; Louis Diehl; Carlos de Castro; Thomas LeBlanc; Danielle Brander; Harry Erba; Ahmed Galal; Alexandra Stefanovic; Nelson Chao; David A Rizzieri
Journal:  Am J Hematol       Date:  2020-03-30       Impact factor: 10.047

2.  Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies.

Authors:  Hiroaki Araie; Yuka Kawaguchi; Motohito Okabe; Yoonha Lee; Marie Ohbiki; Masahide Osaki; Miyo Goto; Tatsunori Goto; Takanobu Morishita; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Int J Hematol       Date:  2019-08-12       Impact factor: 2.490

Review 3.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Authors:  Mitchell S Cairo; Kenneth R Cooke; Hillard M Lazarus; Nelson Chao
Journal:  Br J Haematol       Date:  2020-03-04       Impact factor: 6.998

Review 4.  Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

Authors:  Joseph M Brandwein; Nancy Zhu; Rajat Kumar; Brian Leber; Mitchell Sabloff; Irwindeep Sandhu; Jeannine Kassis; Harold J Olney; Mohamed Elemary; Andre C Schuh
Journal:  Am J Blood Res       Date:  2017-07-25

5.  Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.

Authors:  Yasuhiko Shibasaki; Tatsuya Suwabe; Takayuki Katagiri; Tomoyuki Tanaka; Takashi Ushiki; Kyoko Fuse; Naoko Sato; Toshio Yano; Takashi Kuroha; Shigeo Hashimoto; Miwako Narita; Tatsuo Furukawa; Hirohito Sone; Masayoshi Masuko
Journal:  Int J Hematol       Date:  2018-05-09       Impact factor: 2.490

6.  Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT.

Authors:  Aliénor Xhaard; Renato Cunha; Marc Busson; Marie Robin; Nathalie Dhedin; Tereza Coman; Aurélie Cabannes-Hamy; Flore Sicre de Fontbrune; David Michonneau; Gérard Socié; Rodrigo T Calado; Régis Peffault de Latour
Journal:  Blood Adv       Date:  2017-08-02

7.  Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Authors:  R Chakraborty; E Muchtar; S K Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

Review 8.  From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.

Authors:  Roni Shouval; Arnon Nagler
Journal:  Stem Cell Investig       Date:  2017-05-24

9.  Serum albumin and ferritin levels: a practical indicator of prognosis in acute myeloid leukemia over 50 years of age?

Authors:  Osman Yokus; Erdem Sunger; Tahir Alper Cinli; Hasan Goze; Istemi Serin
Journal:  Am J Blood Res       Date:  2022-06-20

10.  Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Nosha Farhadfar; Ajoy Dias; Tao Wang; Caitrin Fretham; Saurabh Chhabra; Hemant S Murthy; Larisa Broglie; Anita D'Souza; Shahinaz M Gadalla; Robert Peter Gale; Shahrukh Hashmi; A Samer Al-Homsi; Gerhard C Hildebrandt; Peiman Hematti; David Rizzieri; Lynette Chee; Hillard M Lazarus; Christopher Bredeson; Edgar A Jaimes; Amer Beitinjaneh; Asad Bashey; Tim Prestidge; Maxwell M Krem; David I Marks; Stefanie Benoit; Jean A Yared; Taiga Nishihori; Richard F Olsson; Cesar O Freytes; Edward Stadtmauer; Bipin N Savani; Mohamed L Sorror; Siddhartha Ganguly; John R Wingard; Marcelo Pasquini
Journal:  Transplant Cell Ther       Date:  2021-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.